FDA approves cryopreserved formulation of ReNeuron’s candidate
European Pharmaceutical Review | June 27, 2017
The FDA has approved the cryopreserved formulation of ReNeuron’s human retinal progenitor cell (hRPC) therapeutic candidate and have started treating patients with this formulation in their ongoing US Phase I/II study clinical trial in retinitis pigmentosa (RP) patients.